Plaque psoriasis (PsO) is a chronic inflammatory skin disorder that may be 
associated with several comorbidities, including arthritis. The increasing 
knowledge of psoriasis pathogenesis led to the identification of novel targeted 
therapeutic interventions. Among them, anti-IL-17A and anti-IL-17F antibodies 
are currently being investigated for the treatment of PsO and/or psoriatic 
arthritis (PsA). Bimekizumab is one of these agents, capable ofsimultaneously 
neutralizing both IL-17A and IL-17F cytokines. In this review we included 
preclinical and clinical data related to this highly promising agent that shows 
a peculiar molecular structure differing from other bispecific agents.